What is the appropriate cefepime dosing regimen for a 38‑year‑old patient with febrile Escherichia coli pyelonephritis who remains febrile on ceftriaxone, including renal function–based dose adjustments?

Cefepime Dosing for Febrile E. coli Pyelonephritis

For a 38-year-old patient with febrile E. coli pyelonephritis who remains febrile on ceftriaxone, administer cefepime 2 g IV every 12 hours for 7-10 days, with dose adjustments based on creatinine clearance. 1

Standard Dosing for Normal Renal Function

For patients with creatinine clearance (CrCl) >60 mL/min:

• Severe pyelonephritis due to E. coli: 2 g IV every 12 hours for 10 days 1
• Alternative regimen: 1-2 g IV every 12 hours (the 2024 EAU guidelines note that lower doses have been studied, but higher doses are recommended) 2
• Administer each dose as an IV infusion over approximately 30 minutes 1

The FDA-approved dosing specifically indicates 2 g every 12 hours for severe uncomplicated or complicated UTIs including pyelonephritis caused by E. coli or K. pneumoniae 1. This patient's persistent fever on ceftriaxone suggests either a more resistant organism or inadequate tissue penetration, warranting the higher dose.

Renal Function-Based Dose Adjustments

Critical consideration: Patients with augmented renal clearance (CrCl >120 mL/min) may require more frequent dosing, while those with impaired function need interval extension 1, 3.

Dosing by Creatinine Clearance:

• CrCl >120 mL/min: Consider 2 g every 8 hours (standard dosing may be suboptimal due to rapid clearance) 3, 4
• CrCl >60 mL/min: 2 g every 12 hours 1
• CrCl 30-60 mL/min: 2 g every 24 hours 1
• CrCl 11-29 mL/min: 1 g every 24 hours 1
• CrCl <11 mL/min: 500 mg every 24 hours 1
• Hemodialysis: 1 g on day 1, then 500 mg every 24 hours (administer after dialysis on dialysis days) 1

Calculating Creatinine Clearance

Use the Cockcroft-Gault equation when only serum creatinine is available 1:

Males: CrCl (mL/min) = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]

Females: 0.85 × above value

Extended Infusion Considerations

For critically ill patients or infections with organisms having MIC ≥4 mg/L, consider extended infusions (3-hour infusion or continuous infusion) to optimize pharmacodynamic target attainment 5, 6, 7. Standard 30-minute infusions may be suboptimal for less susceptible pathogens, particularly when CrCl exceeds 120 mL/min 4.

Extended infusions improve the time that free drug concentration exceeds the MIC (fT>MIC), which is the critical pharmacodynamic parameter for β-lactams 5, 6. For cefepime, achieving 70% fT>MIC is the target for clinical efficacy, though 100% fT>MIC may be preferred for critically ill patients 6, 7.

Important Safety Considerations

Neurotoxicity Risk

Monitor closely for neurotoxicity, especially in patients with renal impairment 5, 6, 7. Cefepime has higher pro-convulsive activity than most other β-lactams (relative activity 160 compared to penicillin G = 100) 5.

Risk factors for neurotoxicity include:

• Trough concentrations >20 mg/L 5, 6
• Renal impairment without appropriate dose adjustment 6, 7
• Elderly patients 1, 8
• Critically ill patients 7

Clinical Failure on Ceftriaxone

This patient's persistent fever on ceftriaxone warrants consideration of:

• Resistance mechanisms: The E. coli may produce AmpC β-lactamases or ESBLs that are better covered by cefepime 2, 9
• Inadequate tissue penetration: Ceftriaxone has lower urinary concentrations than cefepime in some cases 2
• Obtain cultures and susceptibility testing before switching to guide definitive therapy 10, 2

Duration of Therapy

7-10 days is the recommended duration for complicated pyelonephritis 1. The FDA label specifies 10 days for severe UTIs including pyelonephritis due to E. coli 1, while recent guidelines suggest 7 days may be adequate for uncomplicated cases 10, 2.

For this patient with persistent fever suggesting more severe disease, aim for 10 days of therapy 1.

Therapeutic Drug Monitoring

Consider therapeutic drug monitoring (TDM) in this patient given the clinical failure on ceftriaxone and to optimize the balance between efficacy and neurotoxicity 6, 7. TDM is particularly beneficial in critically ill patients, those with life-threatening infections, or infections with more resistant pathogens 6.

Target trough concentrations should be 4-8 times the MIC for optimal efficacy while minimizing neurotoxicity risk (keeping troughs <20 mg/L) 6, 7.